Abstract
Introduction: Addiction to cocaine is a major problem around the world, but especially in developed countries where the combination of wealth and user demand has created terrible social problems. Although only some users become truly addicted, those who are often succumb to a downward spiral in their lives from which it is very difficult to escape. From the medical perspective, the lack of effective and safe, non-addictive therapeutics has instigated efforts to develop alternative approaches for treatment, including anticocaine vaccines designed to block cocaine's pharmacodynamic effects.Areas covered: This paper discusses the implications of cocaine pharmacokinetics for robust vaccine antibody responses, the results of human vaccine clinical trials, new developments in animal models for vaccine evaluation, alternative vaccine formulations and complementary therapy to enhance anticocaine effectiveness.Expert opinion: Robust anti-cocaine antibody responses are required for benefit to cocaine abusers, but since any reasonably achievable antibody level can be overcome with higher drug doses, sufficient motivation to discontinue use is also essential so that the relative barrier to cocaine effects will be appropriate for each individual. Combining a vaccine with achievable levels of an enzyme to hydrolyze cocaine to inactive metabolites, however, may substantially increase the blockade and improve treatment outcomes.
Original language | English (US) |
---|---|
Pages (from-to) | 1271-1283 |
Number of pages | 13 |
Journal | Expert Opinion on Biological Therapy |
Volume | 14 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2014 |
Keywords
- Addiction
- Adjuvant
- Antibody
- Butyrylcholinesterase
- Cocaine
- Gene therapy
- Hydrolase
- Vaccine
ASJC Scopus subject areas
- Pharmacology
- Clinical Biochemistry
- Drug Discovery